Home' Australian Pharmacist : Australian Pharmacist February 2016 Contents Australian Pharmacist February 2016 I ©Pharmaceutical Society of Australia Ltd.
Ovarian cancer treatment
A strong pipeline of 462 diverse and innovative products in active
development to treat ovarian cancer signals significant potential for
alternatives to chemotherapy, according to business intelligence provider
The company’s report Frontier Pharma:
Ovarian Cancer - Identifying and
Commercializing First-in-Class Innovation
concluded that as the market becomes
more diverse, it will become less reliant
on indiscriminate and highly cytotoxic
chemotherapy regimens, which do
not target specific proteins in aberrant
pathways in ovarian cancer.
GBI Research analyst Joshua Libberton
said that despite limited therapeutic
options for ovarian cancer patients,
almost 52% of ovarian cancer products
in active development in the pipeline
were considered to be first-in-class,
as they have a molecular target not
associated with any marketed products.
He said: ‘As the current ovarian cancer
market has a large generic presence,
and relatively few novel active
pharmaceutical ingredients, the market
has stagnated, leaving a large portion
of the ovarian cancer population with
significant unmet needs.
‘Currently, ovarian cancer has
the highest mortality rate of all
gynaecological cancers and is fatal
in a majority of patients, rendering it
imperative that more effective therapies
According to the Report, the high
proportion of first-in-class innovation
implies that the industry is pursuing novel
approaches to treatment and reducing
the focus on established therapies.
Although innovation to date has been
slow, greater disease understanding and
awareness has created an environment in
which it will thrive.
Mr Libberton said that in addition to
the use of existing platinum-based
chemotherapy, treatments such as
anti-angiogenic treatments and Poly
ADP Ribose Polymerase inhibitors were
expected to have a positive impact on
ovarian cancer survival in particular
‘ The pipeline is showing clear signs of
innovation in ovarian cancer treatment,
with many products deviating away
from standard chemotherapy targets,
and a high proportion of first-in-
class drugs. Despite fewer innovative
products reaching the ovarian cancer
market than other indications in the
past, there is hope that an industry-
wide perception of high rewards for
successful first-in-class products and an
innovative ovarian cancer pipeline can
provide improved treatment options.’
Retention of S8 prescription
BY DENISE L HOPE, STEVEN T DICKFOS &
MICHELLE A KING
Did you know that in New South Wales
, Tasmania2 (s23(2)) and Western
Australia3 (s52(3)(e)) a pharmacist must retain
a patient’s prescription after dispensing
an S8 medicine, irrespective of whether
the prescription has authorised repeats?
This requirement also applies to special
restricted substances (e.g. anabolic
steroids and some barbiturates) in
1 (s42(1)) Retention of repeats has the
potential to inconvenience interstate
1. New South Wales Government. Poisons and Therapeutic
Goods Regulation 2008. 2015. At: www.legislation.nsw.gov.
Accessed 12 Oct 2015.
2. Tasmanian Government. Poisons Regulations 2008. 2015;
prompt=;rec=;term=. Accessed 12 Oct 2015.
3. Government of Western Australia. Poisons Regulations 1965.
2015. At: www.slp.wa.gov.au/legislation/statutes.nsf/main_
mrtitle_1920_homepage.html. Accessed 12 Oct 2015.
4. Hope DL, Dickfos ST, Ellerby RE, King MA. Borderline Health:
Potential Risks to Patients and Practitioners of Jurisdictional
Variation in Australian Medicines Legislation. Journal of
Pharmacy Practice and Research. 2016;(in press).
Denise L Hope, BPharm, MMedRes, GradCertHigherEd;
Lecturer, School of Pharmacy, Griffith University,
Steven T Dickfos, BSc (Oceanography), BPharmaceutSci,
MPharm; Flight Lieutenant, Royal Australian Air Force
(RAAF), Canberra, Australia.
Michelle A King, BPharm, PhD (Med); Senior Lecturer,
Menzies Health Institute Queensland and School of
Pharmacy, Griffith University, Queensland, Australia.
» LEGAL GEMS
4–6 March 2016
Crowne Plaza, Terrigal
2016 ANNUAL THERAPEUTIC UPDATE
Proudly partnered by
Links Archive Australian Pharmacist January 2016 Australian Pharmacist March 2016 Navigation Previous Page Next Page